RT Journal Article
SR Electronic
T1 Face mask fit modifications that improve source control performance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.16.21263642
DO 10.1101/2021.09.16.21263642
A1 Blachere, Francoise M.
A1 Lemons, Angela R.
A1 Coyle, Jayme P.
A1 Derk, Raymond C.
A1 Lindsley, William G.
A1 Beezhold, Donald H.
A1 Woodfork, Karen
A1 Duling, Matthew G.
A1 Boutin, Brenda
A1 Boots, Theresa
A1 Harris, James R.
A1 Nurkiewicz, Tim
A1 Noti, John D.
YR 2021
UL http://medrxiv.org/content/early/2021/09/26/2021.09.16.21263642.abstract
AB BACKGROUND During the COVID-19 pandemic, face masks are used as source control devices to reduce the expulsion of respiratory aerosols from infected people. Modifications such as mask braces, earloop straps, knotting and tucking, and double masking have been proposed to improve mask fit. However, the data on source control are limited.METHODS The effectiveness of mask fit modifications was determined by conducting fit tests on human subjects and simulator manikins and by performing simulated coughs and exhalations using a source control measurement system.RESULTS Medical masks without modification blocked ≥56% of cough aerosols and ≥42% of exhaled aerosols. Modifying fit by crossing the earloops or placing a bracket under the mask did not increase performance, while using earloop toggles, an earloop strap, and knotting and tucking the mask increased performance. The most effective modifications for improving source control performance were double masking and using a mask brace. Placing a cloth mask over a medical mask blocked ≥85% of cough aerosols and ≥91% of exhaled aerosols. Placing a brace over a medical mask blocked ≥95% of cough aerosols and ≥99% of exhaled aerosols.CONCLUSION Fit modifications can greatly improve the performance of face masks as source control devices for respiratory aerosols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch was supported by the following sources: Centers for Disease Control and Prevention, National Institutes of Health R01 ES015022 (TRN) and WV-CTSI U54 GM104942-05.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WVU Protocol #: 2009119037All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from research personnel upon request.